NBY - NovaBay Pharmaceuticals Inc Stock Price, Fair Value and News

0.07USD-0.01 (-12.50%)Market Closed

Market Summary

USD0.07-0.01

Market Closed

-12.50%

NBY Stock Price

View Fullscreen

NBY RSI Chart

NBY Valuation

Market Cap

2.1M

Price/Earnings (Trailing)

-0.22

Price/Sales (Trailing)

0.14

EV/EBITDA

0.11

Price/Free Cashflow

-0.51

NBY Price/Sales (Trailing)

NBY Profitability

EBT Margin

-65.46%

Return on Equity

-290.89%

Return on Assets

-106.71%

Free Cashflow Yield

-196.97%

NBY Fundamentals

NBY Revenue

Revenue (TTM)

14.7M

Rev. Growth (Yr)

2.31%

Rev. Growth (Qtr)

14.15%

NBY Earnings

Earnings (TTM)

-9.6M

Earnings Growth (Yr)

49.94%

Earnings Growth (Qtr)

-133.81%

Breaking Down NBY Revenue

Last 7 days

-12.5%

Last 30 days

-46.2%

Last 90 days

-53.3%

Trailing 12 Months

-94.7%

How does NBY drawdown profile look like?

NBY Financial Health

Current Ratio

1.67

NBY Investor Care

Shares Dilution (1Y)

1379.02%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	14.3M	15.2M	14.6M	14.7M
2022	11.3M	12.8M	14.3M	14.4M
2021	9.8M	8.0M	8.1M	9.8M
2020	7.0M	9.2M	9.8M	9.9M
2019	11.1M	10.0M	8.5M	6.6M
2018	17.5M	16.1M	15.2M	12.5M
2017	13.9M	15.3M	16.0M	18.2M
2016	5.6M	7.2M	9.5M	11.9M
2015	1.4M	2.2M	3.3M	4.4M
2014	2.7M	2.0M	1.1M	1.0M
2013	6.6M	6.5M	4.0M	3.5M
2012	9.8M	6.2M	7.1M	6.9M
2011	10.2M	12.1M	12.8M	11.0M
2010	0	13.7M	11.7M	9.8M
2009	0	0	0	15.7M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of NovaBay Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 11, 2023	zheng yongxiang	acquired	-	-	858	-
May 11, 2023	sit swan	acquired	-	-	858	-
May 11, 2023	garlikov julie	acquired	-	-	858	-
May 11, 2023	wu mijia	acquired	-	-	858	-
May 11, 2023	freiman paul e.	acquired	-	-	858	-
May 11, 2023	zheng yenyou	acquired	-	-	858	-
Dec 06, 2022	kunin jeffrey	sold	-1.81	1.81	-1.00	president, dermadoctor, llc
Dec 06, 2022	kunin audrey	sold	-1.81	1.81	-1.00	chief product officer
Nov 21, 2022	kunin jeffrey	sold	-12,545	2.1049	-5,960	president, dermadoctor, llc
Nov 21, 2022	kunin audrey	sold	-12,545	2.1049	-5,960	chief product officer

Which funds bought or sold NBY recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Mar 11, 2024	VANGUARD GROUP INC	new	-	2,797	2,797	-%
Feb 26, 2024	Virtu Financial LLC	new	-	13,000	13,000	-%
Feb 14, 2024	BANK OF AMERICA CORP /DE/	unchanged	-	-21.00	18.00	-%
Feb 14, 2024	Altium Capital Management LP	new	-	13,761	13,761	0.01%
Feb 14, 2024	TWO SIGMA SECURITIES, LLC	reduced	-42.34	-9,198	3,255	-%
Feb 14, 2024	Hudson Bay Capital Management LP	new	-	11,016	11,016	-%
Feb 14, 2024	Royal Bank of Canada	unchanged	-	-	-	-%
Feb 14, 2024	CITADEL ADVISORS LLC	reduced	-56.94	-30,836	7,479	-%
Feb 13, 2024	GEODE CAPITAL MANAGEMENT, LLC	unchanged	-	-6,165	5,112	-%
Feb 13, 2024	MORGAN STANLEY	unchanged	-	-39.00	32.00	-%

Are Funds Buying or Selling NBY?

Are funds buying NBY calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own NBY

No. of Funds

Unveiling NovaBay Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	armistice capital, llc	4.99%	380,949	SC 13G/A
Feb 13, 2024	altium capital management lp	4.99%	67,457	SC 13G/A
Feb 06, 2024	hudson bay capital management lp	9.99%	718,678	SC 13G/A
Feb 14, 2023	armistice capital, llc	9.99%	191,826	SC 13G
Feb 10, 2023	hudson bay capital management lp	9.99%	225,909	SC 13G/A
Feb 04, 2022	hudson bay capital management lp	9.99%	4,971,292	SC 13G
Aug 24, 2020	fu jian ping	9.6%	4e+06	SC 13D/A
Feb 14, 2020	armistice capital, llc	4.99%	1,465,426	SC 13G/A
Jan 23, 2020	empery asset management, lp	4.43%	1,293,487	SC 13G/A

Recent SEC filings of NovaBay Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
Apr 22, 2024	8-K	Current Report
Apr 19, 2024	8-K	Current Report
Apr 18, 2024	DEFA14A	DEFA14A
Apr 18, 2024	DEF 14A	DEF 14A
Apr 18, 2024	ARS	ARS
Apr 08, 2024	PRE 14A	PRE 14A
Apr 05, 2024	D	D
Mar 29, 2024	10-K/A	Annual Report
Mar 26, 2024	8-K	Current Report
Mar 26, 2024	10-K	Annual Report

Peers (Alternatives to NovaBay Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.6B	6.8B	-1.39%	-19.31%	-8.82	6.07	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.1B	1.8B	-5.44%	-28.86%	-41.14	9.91	76.23%	61.08%
BMRN	17.2B	2.4B	5.41%	-4.57%	102.64	7.11	15.42%	18.43%
INCY	11.6B	3.7B	-9.99%	-29.65%	19.44	3.14	8.87%	75.42%
MID-CAP
APLS	6.0B	396.6M	-10.10%	-42.90%	-11.39	15.18	425.83%	18.94%
BBIO	4.4B	-	-14.83%	70.74%	-6.74	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-7.99%	-0.08%	-14.09	12.46	440.80%	-27.84%
ARWR	2.9B	240.7M	-16.49%	-30.64%	-9.72	12.18	-1.03%	-92.09%
ACAD	2.7B	726.4M	-7.01%	-17.50%	-44.6	3.76	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-4.67%	-6.03%	24.96	4.48	85.90%	-14.05%
NVAX	580.8M	983.7M	-13.72%	-45.61%	-1.07	0.59	-50.36%	17.16%
CRBP	372.9M	881.7K	-0.25%	294.45%	-8.36	466.16	-77.61%	-5.33%
INO	237.4M	4.9M	-18.06%	3.25%	-1.76	48.79	-54.97%	51.71%
IBIO	6.6M	2.1M	70.91%	57.98%	-0.24	2.14	-13.45%	66.37%

NovaBay Pharmaceuticals Inc News

Latest updates

NovaBay Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	14.2%	3,727,000	3,265,000	4,610,000	3,124,000	3,643,000	3,826,000	3,662,000	3,273,000	3,586,000	2,265,000	2,133,000	1,807,000	1,888,000	2,170,000	3,984,000	1,892,000	1,704,000	1,615,000	1,789,000	1,491,000	3,625,000
Gross Profit	-1.3%	1,815,000	1,838,000	2,306,000	1,936,000	1,754,500	2,375,000	1,838,000	1,814,000	1,884,500	1,553,000	1,519,000	1,352,000	1,075,000	1,634,000	1,944,000	1,311,000	1,111,000	1,214,000	1,386,000	1,150,000	3,184,000
Operating Expenses	76.2%	5,206,000	2,954,000	3,661,000	3,670,000	11,180,500	2,832,000	3,990,000	4,196,000	5,078,500	3,842,000	3,378,000	2,872,000	2,833,000	3,696,000	3,015,000	2,846,000	3,349,000	2,926,000	2,765,000	5,221,000	4,795,000
S&GA Expenses	-17.6%	1,414,000	1,715,000	1,718,000	1,653,000	1,938,000	1,835,000	2,040,000	1,985,000	2,357,500	2,061,000	1,788,000	1,680,000	1,498,000	1,692,000	1,423,000	1,560,000	2,157,000	1,544,000	1,535,000	3,531,000	3,186,000
R&D Expenses	-63.6%	4,000	11,000	27,000	26,000	65,500	41,000	40,000	28,000	8,000	10,000	21,000	5,000	36,000	125,000	115,000	9,000	18,000	49,000	32,000	85,000	107,000
EBITDA Margin	31.6%	-0.63	-0.92	-0.79	-0.85	-0.73	-0.17	-0.36	-0.38	-0.59	-0.91	-1.04	-1.11	-1.10	-1.21	-	-	-	-	-	-	-
Interest Expenses	-23.9%	137,000	180,000	4,000	5,000	5,000	5,000	3,000	4,000	-	-	-	-	-12,000	6,000	20,000	35,000	-	-	-	-	-
Income Taxes	-	-	-	-	-	24,000	-	-	-	21.00	-	-	-	4,000	-	1,000	-	3,000	-	2,000	1,000	3,000
Earnings Before Taxes	-133.8%	-4,108,000	-1,757,000	-2,036,000	-1,739,000	-8,206,000	-136,000	-2,155,000	-111,000	-158,000	-2,289,000	-1,859,000	-1,518,000	-1,750,000	-3,221,000	-4,481,000	-1,582,000	-2,683,000	-282,000	-2,499,000	-4,188,000	-1,265,000
EBT Margin	30.2%	-0.65	-0.94	-0.80	-0.86	-0.74	-0.18	-0.37	-0.39	-0.59	-0.92	-1.04	-1.11	-1.11	-1.23	-	-	-	-	-	-	-
Net Income	-133.8%	-4,108,000	-1,757,000	-2,036,000	-1,739,000	-8,206,000	-136,000	-2,155,000	-111,000	-158,000	-2,289,000	-1,859,000	-1,518,000	-1,754,000	-3,221,000	-4,482,000	-1,582,000	-2,686,000	-282,000	-2,501,000	-4,189,000	-1,268,000
Net Income Margin	30.2%	-0.65	-0.94	-0.80	-0.86	-0.74	-0.18	-0.37	-0.39	-0.59	-0.92	-1.04	-1.11	-1.11	-1.23	-	-	-	-	-	-	-
Free Cashflow	13.4%	-316,000	-365,000	-1,845,000	-1,624,000	-1,209,000	-1,769,000	-1,707,000	-2,081,000	-4,326,000	-1,485,000	-1,989,000	-1,444,000	-1,466,000	-1,375,000	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-29.7%	9,034	12,852	16,008	14,825	16,399	22,376	21,544	24,794	23,978	12,239	13,603	14,072	15,238	17,082	13,272	9,475	11,220	14,603	9,870	9,720	9,361
Current Assets	-12.9%	7,154	8,214	11,216	9,894	11,332	10,613	9,459	12,478	13,170	11,497	12,772	13,146	14,242	16,012	11,908	7,874	9,381	12,498	7,496	7,115	8,608
Cash Equivalents	-9.9%	3,130	3,472	4,414	3,746	5,362	3,868	3,931	5,641	7,504	9,028	10,294	10,508	11,952	13,413	8,775	5,708	6,937	9,020	3,668	2,932	3,183
Inventory	-17.6%	2,877	3,493	3,660	3,797	3,437	4,068	3,801	3,437	3,220	969	682	850	608	785	626	552	492	838	664	302	280
Net PPE	-10.3%	87.00	97.00	108	119	119	217	166	187	193	96.00	94.00	100	84.00	76.00	84.00	97.00	110	128	177	193	201
Goodwill	-100.0%	-	348	348	348	348	4,528	4,500	4,500	4,528	-	-	-	-	-	-	-	-	-	-	-	-
Liabilities	-1.6%	5,720	5,815	7,445	5,935	5,845	8,592	5,799	7,048	13,807	2,875	2,394	3,089	2,920	3,200	12,289	9,824	10,247	11,096	8,201	8,591	4,407
Current Liabilities	-6.4%	4,278	4,571	6,066	4,423	4,257	3,710	3,657	4,784	3,442	2,874	2,389	3,080	2,833	3,003	4,301	5,483	5,687	6,252	3,352	5,414	3,847
LT Debt, Current	-10.5%	1,137	1,270	1,185	-	-	-	-	-	-	-	-	-	-	-	418	954	1,409	1,890	-	-	-
Shareholder's Equity	-52.9%	3,314	7,037	8,563	8,890	10,554	13,784	15,745	17,746	10,171	9,364	11,209	10,983	12,318	13,882	983	-	973	2,923	1,669	1,129	4,954
Retained Earnings	-5.5%	-174,849	-165,680	-163,923	-159,891	-158,152	-149,946	-144,153	-141,998	-141,887	-141,729	-139,440	-137,581	-136,063	-134,309	-131,088	-126,606	-125,024	-122,338	-122,056	-119,526	-114,981
Additional Paid-In Capital	3.2%	176,101	170,675	169,689	165,156	165,713	162,510	158,793	158,621	150,900	150,643	150,202	148,146	147,963	147,774	131,725	125,975	125,718	125,009	123,518	120,484	119,764
Shares Outstanding	72.0%	11,230	6,529	4,214	2,035	2,035	1,514	1,507	1,431	1,365	1,231	1,205	1,194	1,194	-	-	-	-	-	-	-	-
Float	-	-	-	3,050	-	-	-	10,875	-	-	-	23,677	-	-	-	26,683	-	-	-	15,628	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	13.5%	-314	-363	-1,843	-1,611	-1,209	-1,689	-1,699	-2,057	-4,318	-1,468	-1,987	-1,419	-1,445	-1,370	-1,041	-865	-1,429	-1,500	-1,779	-3,221	-1,993
Cashflow From Investing	0%	-2.00	-2.00	-2.00	-13.00	-	-80.00	-8.00	-24.00	-12,001	-17.00	-2.00	-25.00	-21.00	-5.00	-	-	-	-	-5.00	-14.00	-31.00
Cashflow From Financing	95.5%	-26.00	-577	2,513	-	3,035	1,703	-	-105	14,795	219	1,775	-	5.00	6,013	4,108	-364	-654	6,852	2,520	2,984	-

NBY Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Sales:
Total sales, net	$ 14,726	$ 14,404
Cost of goods sold	6,831	6,623
Gross profit	7,895	7,781
Operating expenses
Research and development	68	174
Sales and marketing	6,500	7,798
General and administrative	6,330	7,489
Goodwill, intangible and other asset impairment	2,593	6,737
Total operating expenses	15,491	22,198
Operating loss	(7,596)	(14,417)
Non-cash gain on changes in fair value of warrant liability	272	5,446
Non-cash gain on changes in fair value of embedded derivative liability	40	0
Non-cash gain on changes in fair value of contingent liability	0	561
Non-cash loss on modification of common stock warrants	(292)	(1,922)
Other expense, net	(2,064)	(276)
Net loss	(9,640)	(10,608)
Less: Increase to accumulated deficit due to adjustment to Preferred Stock conversion prices	7,057	5,657
Net loss attributable to common stockholders	$ (16,697)	$ (16,265)
Net loss per share attributable to common stockholders (basic and diluted)* (in dollars per share)	$ (3.96)	$ (10.1)
Weighted-average shares of common stock outstanding used in computing net loss per share of common stock (basic and diluted)* (in shares)	4,215	1,610
Product [Member]
Sales:
Total sales, net	$ 14,687	$ 14,374
Product and Service, Other [Member]
Sales:
Total sales, net	$ 39	$ 30

NBY Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
ASSETS
Cash and cash equivalents	$ 3,130	$ 5,362
Accounts receivable, net of allowance for credit losses ($3 and $19 at December 31, 2023 and 2022, respectively)	759	1,973
Inventory, net of allowance for excess and obsolete inventory and lower of cost or estimated net realizable value adjustments ($627 and $499 at December 31, 2023 and 2022, respectively)	2,877	3,437
Prepaid expenses and other current assets	388	560
Total current assets	7,154	11,332
Operating lease right-of-use assets	1,296	1,831
Property and equipment, net	87	119
Goodwill	0	348
Other intangible assets, net	0	2,280
Other assets	497	489
TOTAL ASSETS	9,034	16,399
LIABILITIES AND STOCKHOLDERS’ EQUITY
Accounts payable	1,130	1,080
Accrued liabilities	1,516	2,724
Secured Convertible Notes, net of discounts	1,137	0
Operating lease liability	495	453
Total current liabilities	4,278	4,257
Warrant liability	334	0
Operating lease liabilities-non-current	1,108	1,588
Total liabilities	5,720	5,845
Commitments and contingencies (Note 10)
Stockholders’ equity:
Common stock, $0.01 par value; 150,000 shares authorized, 11,230 and 2,035 shares issued and outstanding at December 31, 2023 and 2022, respectively*	112	20
Additional paid-in capital*	176,101	165,713
Accumulated deficit	(174,849)	(158,152)
Total stockholders’ equity	3,314	10,554
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	9,034	16,399
Series B Preferred Stock [Member]
Stockholders’ equity:
Preferred Stock	275	570
Series C Preferred Stock [Member]
Stockholders’ equity:
Preferred Stock	$ 1,675	$ 2,403

About NovaBay Pharmaceuticals Inc

NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through traditional and digital beauty retailers and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.

CEO	Mr. Justin M. Hall Esq.
WEBSITE	https://novabay.com
INDUSTRY	Biotechnology
EMPLOYEES	29

NovaBay Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for NovaBay Pharmaceuticals Inc? What does NBY stand for in stocks?

NBY is the stock ticker symbol of NovaBay Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of NovaBay Pharmaceuticals Inc (NBY)?

As of Wed Apr 24 2024, market cap of NovaBay Pharmaceuticals Inc is 2.11 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of NBY stock?

You can check NBY's fair value in chart for subscribers.

What is the fair value of NBY stock?

You can check NBY's fair value in chart for subscribers. The fair value of NovaBay Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of NovaBay Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for NBY so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is NovaBay Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether NBY is over valued or under valued. Whether NovaBay Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact NovaBay Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NBY.

What is NovaBay Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Apr 24 2024, NBY's PE ratio (Price to Earnings) is -0.22 and Price to Sales (PS) ratio is 0.14. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NBY PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on NovaBay Pharmaceuticals Inc's stock?

In the past 10 years, NovaBay Pharmaceuticals Inc has provided -0.611 (multiply by 100 for percentage) rate of return.